ERBB2 and breast cancer: Multiple HER2-targeted therapies, including the monoclonal antibody trastuzumab and small molecule tyrosine kinase inhibitors (TKIs) have been approved for the treatment of HER2-overexpressing (HER2+) breast cancer (Goutsouliak et al, 2020).